SCHEMBL4210043

SCHEMBL4210043

O=C(O)c1ccc2c(C3CCCCC3)c3n(c2c1)C[C@H](O)COc1cc(OCc2ccccn2)ccc1-3

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 1/20 0.54
MMP12 P39900 1/20 0.54
GPR84 Q9NQS5 3/20 0.36
ALOX5 P09917 1/20 0.36
PARP10 Q53GL7 1/20 0.36
P2RY12 Q9H244 1/20 0.35
CYP3A4 P08684 5/20 0.34
CYP2C19 P33261 5/20 0.34
CYP2C9 P11712 3/20 0.34
CYP2D6 P10635 1/20 0.34
NR1I2 O75469 2/20 0.34
BRD4 O60885 1/20 0.34
CREBBP Q92793 1/20 0.34
RHOA P61586 1/20 0.34
CYP1A2 P05177 1/20 0.34
VDR P11473 2/20 0.34
NR1H4 Q96RI1 2/20 0.34
CSNK2A2 P19784 1/20 0.33
CSNK2A1 P68400 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2273051 0.93 PRKCA (0.48) PRKCAMMP12GPR84PARP10CYP3A4
SCHEMBL4221778 0.92 PRKCA (0.54) PRKCAMMP12GPR84ALOX5PARP10
SCHEMBL2273056 0.89 PRKCA (0.49) PRKCAMMP12ALOX5PARP10CYP3A4
SCHEMBL2272974 0.85 PRKCA (0.48) PRKCAMMP12GPR84PARP10CYP3A4
SCHEMBL2278327 0.83 PRKCA (0.62) PRKCAMMP12GPR84CYP3A4CYP2C19
SCHEMBL3079634 0.83 PRKCA (0.71) PRKCAMMP12CYP3A4CYP2C19CYP2C9
SCHEMBL3080762 0.83 PRKCA (0.71) PRKCAMMP12CYP3A4CYP2C19CYP2C9
SCHEMBL4215913 0.82 PRKCA (0.51) PRKCAMMP12ALOX5CYP3A4CYP2C19
SCHEMBL3086850 0.80 PRKCA (0.57) PRKCAMMP12CYP3A4CYP2C19NR1I2
SCHEMBL772182 0.79 PRKCA (0.51) PRKCAMMP12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090048239-A1 Therapeutic compounds MSD ITALIA S.R.L. (IT) 2009-02-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048239-A1 Therapeutic compounds RRP1B, RCE1, CTSZ PRKCA 4250/4885MMP12 2067/4885GPR84 2937/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.